| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 13 Nov 2025 | 8 Nov 2025 |
| Aarey Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 inter alia to consider and approve This is to intimate that the meeting of the Board of Directors of the Company is scheduled to be held on Thursday 13th November 2025 to transact the following business: 1. To consider and approve the Unaudited Financial Result along with Limited review Report for the quarter and half year ended 30th September 2025. 2. Any other matter with consent of the Chairman. Outcome of Board meeting for approval of Unaudited Financial Results for the quarter and half year ended 30th September, 2025 (As Per BSE Announcement Dated on: 13/11/2025) | ||
| Board Meeting | 3 Sep 2025 | 3 Sep 2025 |
| Pursuant to Regulation 30 (read with Part A of Schedule 1ll) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we wish to inform you that a meeting of the Board of Directors of the Company was held today, i.e., Wednesday, 03 September, 2025 at 05:00 P.M. at the registered office of the Company With reference to the Outcome submitted yesterday i.e., on 03.09.2025 we would like to clarify that due to inadvertent error in Point No. 2 of the Outcome, the time of the Annual General Meeting was mentioned as 11:00 P.M. instead of 11:00 A.M. (As Per BSE Announcement Dated on: 04/09/2025) | ||
| Board Meeting | 13 Aug 2025 | 7 Aug 2025 |
| Aarey Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2025 inter alia to consider and approve This is to intimate that the meeting of the Board of Directors of the Company is scheduled to be held on Wednesday 13th August 2025 to transact the following business: 1. To consider and approve the Unaudited Financial Result along with Limited review Report for the First quarter ended 30th June 2025. 2. Any other matter with consent of the Chairman. Outcome of Board Meeting held on today i.e 13th August, 2025 (As Per BSE Announcement Dated on: 13.08.2025) | ||
| Board Meeting | 30 May 2025 | 22 May 2025 |
| Aarey Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 inter alia to consider and approve This is to intimate that the meeting of the Board of Directors of the Company is scheduled to be held on Friday 30th May 2025 to transact the following business: 1. To consider and approve the Audited Financial statement for the quarter and year ended 31st March 2025. 2. Any other matter with consent of the Chair This is to inform you that the Board of Directors of the Company at its Meeting held today i.e. 30th May, 2025 have passed the following resolution. 1. The Board of Directors of the Company has considered and approved the Standalone Audited Financial Results for the quarter and year ended 31st March, 2025 along with the, Statement of Asset and Liabilities, Result, Cash flow, Audit Report, declaration on unmodified opinion, MD/CFO certification. (As Per BSE Announcement Dated on: 30/05/2025) | ||
| Board Meeting | 23 May 2025 | 23 May 2025 |
| Allotment of Convertible Warrants pursuant to Preferential Issue. | ||
| Board Meeting | 14 Feb 2025 | 6 Feb 2025 |
| AAREY DRUGS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2025 inter alia to consider and approve DEcember Quarterly financial result outcome (As Per Bse Announcement Dated on 14.02.2025) | ||
| Board Meeting | 2 Jan 2025 | 2 Jan 2025 |
| Reg 30 of SEBI (Listing Obligation and Disclosure Requirements)- Resignation of Company Secretary | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.